CN112899307A - Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors - Google Patents
Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors Download PDFInfo
- Publication number
- CN112899307A CN112899307A CN202110121175.8A CN202110121175A CN112899307A CN 112899307 A CN112899307 A CN 112899307A CN 202110121175 A CN202110121175 A CN 202110121175A CN 112899307 A CN112899307 A CN 112899307A
- Authority
- CN
- China
- Prior art keywords
- glun1
- myristoylated
- application
- glun2
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 title claims abstract description 40
- 101710121995 Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 title claims abstract description 40
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 title claims abstract description 31
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 title claims abstract description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims abstract description 28
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 claims abstract description 19
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 claims abstract description 13
- 101710195153 Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 claims abstract description 13
- 230000007498 myristoylation Effects 0.000 claims abstract description 13
- 230000004048 modification Effects 0.000 claims abstract description 10
- 238000012986 modification Methods 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 6
- 229940079593 drug Drugs 0.000 claims abstract description 5
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 4
- 208000025966 Neurological disease Diseases 0.000 claims abstract description 4
- 238000011161 development Methods 0.000 claims abstract description 4
- 208000029726 Neurodevelopmental disease Diseases 0.000 claims abstract 3
- 108091036078 conserved sequence Proteins 0.000 claims description 15
- 230000004807 localization Effects 0.000 claims description 12
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 claims description 9
- 101710195187 Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 claims description 9
- 230000026731 phosphorylation Effects 0.000 claims description 9
- 238000006366 phosphorylation reaction Methods 0.000 claims description 9
- 239000013612 plasmid Substances 0.000 claims description 9
- 150000001413 amino acids Chemical group 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 4
- 230000001123 neurodevelopmental effect Effects 0.000 claims description 3
- 239000002773 nucleotide Substances 0.000 claims description 3
- 125000003729 nucleotide group Chemical group 0.000 claims description 3
- 238000009509 drug development Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract description 5
- 229930195729 fatty acid Natural products 0.000 abstract description 5
- 239000000194 fatty acid Substances 0.000 abstract description 5
- 150000004665 fatty acids Chemical class 0.000 abstract description 5
- 230000018109 developmental process Effects 0.000 abstract description 3
- 230000033228 biological regulation Effects 0.000 abstract description 2
- 230000002427 irreversible effect Effects 0.000 abstract description 2
- 230000007472 neurodevelopment Effects 0.000 abstract description 2
- 210000000170 cell membrane Anatomy 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 230000026792 palmitoylation Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 2
- 150000001295 alanines Chemical class 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- UESYBOXFJWJVSB-AVGNSLFASA-N Gln-Phe-Ser Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(O)=O UESYBOXFJWJVSB-AVGNSLFASA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- IUYCGMNKIZDRQI-BQBZGAKWSA-N Met-Gly-Ala Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(O)=O IUYCGMNKIZDRQI-BQBZGAKWSA-N 0.000 description 1
- 102000015695 Myristoylated Alanine-Rich C Kinase Substrate Human genes 0.000 description 1
- 108010063737 Myristoylated Alanine-Rich C Kinase Substrate Proteins 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical class CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 108010044940 alanylglutamine Proteins 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/02—Drug screening
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Plant Pathology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明公开了一种GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用，本发明提供了GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体的应用，所述应用是将GluN1和/或GluN2亚基羧基末端豆蔻酰化的NMDA受体应用于神经发育或神经疾病药物的开发。本发明中豆蔻酰化的GluN2A羧基末端是一种不可逆的脂肪酸修饰，能够直接转染细胞，用于研究豆蔻酰化对GluN2A功能的调控，在医药等领域具有较广泛的应用前景。
The present invention discloses the application of a myristoylated NMDA receptor at the carboxyl terminal of GluN1 and/or GluN2 subunit, and the present invention provides the application of the myristoylated NMDA receptor at the carboxyl terminal of GluN1 and/or GluN2 subunit. The application is the application of GluN1 and/or GluN2 subunit carboxyl-terminal myristoylated NMDA receptors to the development of drugs for neurodevelopment or neurological diseases. The carboxyl terminus of myristoylated GluN2A in the present invention is an irreversible fatty acid modification, which can be directly transfected into cells and used to study the regulation of the function of GluN2A by myristoylation, and has broad application prospects in the fields of medicine and the like.
Description
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to application of a GluN1 and/or GluN2 subunit carboxyl terminal myristoylation NMDA receptor.
Background
In the field of biology, mutations and aberrant expression of the NMDA receptor have a serious impact on cerebral neurodegeneration and the treatment of related neurological disorders. The study of NMDA receptor structure and function has been a focus in the neuroscience field. The classical NMDA receptor consists of two GluN1 subunits and two GluN2(2A/2B) subunits, which are multi-transmembrane proteins, which all add to the difficulty of studying NMDA receptors. The existing research shows that the NMDA receptor carboxyl terminal controls the signal transduction function, and the research on the NMDA receptor carboxyl terminal is very important for developing corresponding drug targets. Early studies found that palmitoylation could modulate NMDA receptor function by modifying the GluN2A and GluN2B subunits of the NMDA receptor. Palmitoylation is a fatty acid modification that can localize proteins to the cell membrane, which provides a convenience for the study of NMDA receptors. Palmitoylation can position the carboxyl terminal of the NMDA receptor on a cell membrane, so that the positioning of normal NMDA receptor subunits in cells can be simulated, and the function of the NMDA receptor in a normal state can be simulated more truly. However, palmitoylation-modified NMDA receptors present modified abscission and large amounts of unmodified proteins, which limits the utility of this modification.
Disclosure of Invention
In order to solve the technical problems, the invention provides application of GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor.
The first purpose of the invention is to provide an application of GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor, wherein the application is to apply GluN1 and/or GluN2 subunit carboxyl terminal myristoylated NMDA receptor to the development of neurodevelopmental or neuropathy medicines.
Further, the myristoylation is performed by adding a conserved sequence capable of being myristoylated at the carboxy terminus of GluN1 and/or GluN 2.
Furthermore, the amino acid sequence of the conserved sequence is shown as SEQ ID NO. 1.
Further, the nucleotide sequence of the conserved sequence is shown as SEQ ID NO. 2.
Further, primer pairs of GluN1 added with conserved sequences are shown as SEQ ID NO.3 and SEQ ID NO. 4.
Further, in GluN2 added with a conserved sequence, a primer pair of GluN2A is shown as SEQ ID NO.5 and SEQ ID NO. 6; primer pairs of GluN2B are shown as SEQ ID NO.7 and SEQ ID NO. 8.
Further, in the use, there is included modulating membrane localization of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors with positively charged amino acids.
Further, in the use, modulation of membrane localization of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors with phosphorylation modifications is also included.
It is a second object of the present invention to provide a plasmid expressing GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptor.
The third purpose of the invention is to provide the application of the plasmid in the development of medicines for neurodevelopment or neuropathy.
By the scheme, the invention at least has the following advantages:
the carboxyl terminal of the myristoylated GluN2A is an irreversible fatty acid modification, can directly transfect cells, is used for researching the regulation and control of the myristoylation on GluN2A functions, and has wide application prospects in the fields of medicines and the like.
The foregoing is a summary of the present invention, and in order to provide a clear understanding of the technical means of the present invention and to be implemented in accordance with the present specification, the following is a preferred embodiment of the present invention and is described in detail below.
Drawings
FIG. 1 is a fluorescent plot of the carboxyl terminus of myristoylated GluN1 expressed in cells;
FIG. 2 is a fluorescent plot of intracellular expression of myristoylated GluN2A and GluN2B carboxyl termini;
FIG. 3 is a fluorescent map of the carboxyl terminus localization of myristoylated GluN1 to cell membrane;
FIG. 4 is a fluorescent control plot of myristoylated GluN1 with phosphorylation-modified carboxy-terminal localization.
Detailed Description
Example 1:
construction of the carboxyl termini of myristoylated GluN1, GluN2A and GluN2B:
(1) the myristoylation conserved sequence is derived from the protein MARCKS front-end sequence: MGAQFSK.
The corresponding nucleotides are: ATGGGTGCCCAGTTCTCCAAG are provided.
(2) Primers were custom made with the myristoylation conserved sequence as follows:
GluN1:5 '-3' (with myristoylation conserved sequence): TCGGCTAGCACCATG GGTGCCCAGTTCTCCAAGATCGCCTACAAGCGACACAAGGATGCC, respectively; 3'-5': AGCTGTCGACGCTCTCCCTATGACGGGAACACAGCTGCAG are provided.
GluN2A:5 '-3' (with myristoylation conserved sequence): TCGGCTAGCACCATG GGTGCCCAGTTCTCCAAGACCTCTTCTACTGGAAGCTGCGCTTCTG, respectively; 3'-5': AGCTGTCGACAACATCAGATTCGATACTAGGCATTTTC are provided.
GluN2B:5 '-3' (with myristoylation conserved sequence): TCGGCTAGCACCATG GGTGCCCAGTTCTCCAAGCATCTGTTCTATTGGCAGTTCCGGCATTG, respectively; 3'-5': AGCTGTCGACGACATCAGACTCAATACTAGAAAGTTTC are provided.
(3) GluN1, GluN2A and GluN2B plasmids were used as templates for conventional PCR. (PCR kit available from TaKaRa Co., Ltd.) system. The PCR system (25. mu.L) was as follows (unit:. mu.L):
10×Buffer:2.5,
dNTP:2,
Taq:0.5；
primer:2；
vector:300ng。
(4) performing PCR, wherein the PCR conditions are as follows:
(4.1) one cycle, 30 seconds at 95 ℃;
(4.2)30 cycles of 95 ℃ for 30 seconds, 58 ℃ for 30 seconds and 72 ℃ for 2 minutes;
(4.3) one cycle, 10 minutes at 72 ℃.
(5) Agarose gel electrophoresis was performed, and the nucleic acid gel was recovered and digested with NEB fast-cutting enzymes Nhe I and Sal I for 20 minutes. The pEGFP-N3 vector is connected, and the bacteria are selected to be correctly sequenced after transformation and plating.
Example 2:
expression of the carboxyl terminus of myristoylated GluN1:
the myristoylated carboxy-terminal plasmid was transfected into HEK293 cells and after 24 hours the fluorescent signal was detected. The results are shown in FIG. 1 (scale bar: 20 μm), and it can be seen that this myristoylated GluN1 carboxy terminus is well expressed in eukaryotic cells. The invention provides a tool for researching fatty acid modified GluN 1.
Expression of myristoylated GluN2A and GluN2B carboxyl termini:
the myristoylated carboxy-terminal plasmid was transfected into HEK293 cells and after 24 hours the fluorescent signal was detected. The results are shown in FIG. 2 (scale: 20 μm), and it can be seen that this myristoylated GluN2A and GluN2B carboxy terminus are well expressed in eukaryotic cells. The invention provides a tool for researching fatty acid modified GluN 2.
Example 3:
localization of the carboxyl terminus of myristoylated GluN1 was regulated by positively charged amino acids:
the plasmid myristoylated GluN1 carboxyl-terminal was transfected into HEK293 cells and fluorescence signals were detected 24 hours later. The results are shown in FIG. 3 (scale: 20 μm), and the box shows that the carboxyl terminus of this myristoylated GluN1 is able to localize to the cell membrane.
The carboxy terminus of GluN1 contained a 9 positively charged C1 region. Mutating the 10 positively charged amino acids of the C1 region to uncharged alanines (fig. 3A) can significantly reduce the cell membrane localization of the carboxyl terminus of the myristoylated GluN1 (fig. 3B).
Example 4:
localization of the carboxyl terminus of myristoylated GluN1 was regulated by phosphorylation modifications:
the plasmid myristoylated GluN1 carboxyl-terminal was transfected into HEK293 cells and fluorescence signals were detected 24 hours later. The results are shown in FIG. 4 (scale bar: 20 μm), and it can be seen in the box that the localization of the cell membrane at the carboxy terminus of this myristoylated GluN1 was regulated by phosphorylation modification.
GluN1 has 6 sites (tyrosine T and serine S) at the carboxy-terminal C1 region that can be modified by phosphorylation (FIG. 4A). Mutation of the 6 phosphorylation sites in the C1 region to alanines that could not be modified by phosphorylation (FIG. 4B) did not alter the cell membrane localization of the carboxyl terminus of myristoylated GluN 1. However, if 6 phosphorylation sites in the C1 region were mutated to mimic phosphorylation modified glutamate (E) and aspartate (D) (fig. 4B), the cell membrane localization of the carboxyl terminus of myristoylated GluN1 could be significantly reduced (fig. 4C).
The above is only a preferred embodiment of the present invention, and is not intended to limit the present invention, it should be noted that, for those skilled in the art, many modifications and variations can be made without departing from the technical principle of the present invention, and these modifications and variations should also be regarded as the protection scope of the present invention.
Sequence listing
<110> Suzhou university
<120> use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors
<141> 2021-01-28
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 7
<212> PRT
<213> (Artificial sequence)
<400> 1
Met Gly Ala Gln Phe Ser Lys
1 5
<210> 2
<211> 21
<212> DNA
<213> (Artificial sequence)
<400> 2
atgggtgccc agttctccaa g 21
<210> 3
<211> 60
<212> DNA
<213> (Artificial sequence)
<400> 3
tcggctagca ccatgggtgc ccagttctcc aagatcgcct acaagcgaca caaggatgcc 60
<210> 4
<211> 40
<212> DNA
<213> (Artificial sequence)
<400> 4
agctgtcgac gctctcccta tgacgggaac acagctgcag 40
<210> 5
<211> 61
<212> DNA
<213> (Artificial sequence)
<400> 5
tcggctagca ccatgggtgc ccagttctcc aagacctctt ctactggaag ctgcgcttct 60
g 61
<210> 6
<211> 38
<212> DNA
<213> (Artificial sequence)
<400> 6
agctgtcgac aacatcagat tcgatactag gcattttc 38
<210> 7
<211> 62
<212> DNA
<213> (Artificial sequence)
<400> 7
tcggctagca ccatgggtgc ccagttctcc aagcatctgt tctattggca gttccggcat 60
tg 62
<210> 8
<211> 38
<212> DNA
<213> (Artificial sequence)
<400> 8
agctgtcgac gacatcagac tcaatactag aaagtttc 38
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110121175.8A CN112899307A (en) | 2021-01-28 | 2021-01-28 | Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110121175.8A CN112899307A (en) | 2021-01-28 | 2021-01-28 | Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112899307A true CN112899307A (en) | 2021-06-04 |
Family
ID=76119946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110121175.8A Pending CN112899307A (en) | 2021-01-28 | 2021-01-28 | Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112899307A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022246934A1 (en) * | 2021-05-28 | 2022-12-01 | 苏州大学 | Myristoylated polypetide encoding mitochondrial localization, and preparation method therefor and use thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060057614A1 (en) * | 2004-08-04 | 2006-03-16 | Nathaniel Heintz | Tethering neuropeptides and toxins for modulation of ion channels and receptors |
| WO2020101740A1 (en) * | 2018-11-16 | 2020-05-22 | Codiak Biosciences, Inc. | Engineered extracellular vesicles and uses thereof |
-
2021
- 2021-01-28 CN CN202110121175.8A patent/CN112899307A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060057614A1 (en) * | 2004-08-04 | 2006-03-16 | Nathaniel Heintz | Tethering neuropeptides and toxins for modulation of ion channels and receptors |
| WO2020101740A1 (en) * | 2018-11-16 | 2020-05-22 | Codiak Biosciences, Inc. | Engineered extracellular vesicles and uses thereof |
Non-Patent Citations (3)
| Title |
|---|
| BRYCE VISSEL等: "A use-dependent tyrosine dephosphorylation of NMDA receptors is independent of ion flux", 《NATURE NEUROSCIENCE》 * |
| 傅展燕: "活细胞可视化研究NMDA受体在神经元的表面表达、分布及其与突触形成和功能的关系", 《中国博士学位论文全文数据库》 * |
| 郑婵颖等: "NMDA受体 NR2A亚单位C末端突变体在HEK293细胞的共表达研究", 《浙江大学学报（医学版）》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022246934A1 (en) * | 2021-05-28 | 2022-12-01 | 苏州大学 | Myristoylated polypetide encoding mitochondrial localization, and preparation method therefor and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11525125B2 (en) | Modified helicases | |
| US10752948B2 (en) | Alpha-hemolysin variants | |
| JP7027334B2 (en) | Alpha hemolysin variants and their use | |
| CA2879261C (en) | Modified helicases | |
| US20180230526A1 (en) | Enzyme construct | |
| Legrain et al. | The molecular characterization of PRP6 and PRP9 yeast genes reveals a new cysteine/histidine motif common to several splicing factors. | |
| US20070275391A1 (en) | Novel g-protein coupled receptors and dna sequences thereof | |
| US20180245147A1 (en) | Polymerase variants | |
| CN111269325B (en) | Fusion protein of light-regulated BK channel and preparation method and application thereof | |
| CN109071678A (en) | Nerve growth factor fusion protein, preparation method and its usage | |
| CN108449941A (en) | OmpG variant | |
| AU2022200678A1 (en) | Nucleic acid molecules containing spacers and methods of use thereof | |
| CN112899307A (en) | Use of GluN1 and/or GluN2 subunit carboxy-terminal myristoylated NMDA receptors | |
| CN102671185A (en) | Application of scolopendra mutilans neurotoxin peptide omega-SLPTX-Ssmla | |
| WO2020054868A1 (en) | Photoresponsive protein and utilization thereof | |
| CN113307886A (en) | Myristoylation polypeptide for encoding mitochondrial localization and preparation method and application thereof | |
| JPH04144684A (en) | Endothelin receptor | |
| Kim et al. | New fast BiFC plasmid assay system for in vivo protein-protein interactions | |
| CN114057893B (en) | Myristoylation polypeptide for encoding mitochondrial localization and preparation method and application thereof | |
| WO2003057827A3 (en) | Insulin-responsive dna binding protein-1 and methods to regulate insulin-responsive genes | |
| Turek et al. | The discovery of hidden guanylate cyclases (GCs) in the Homo sapiens proteome | |
| Al-Khalilt et al. | Cloning of the proto-oncogene c-src from rat testis | |
| EP1098973A1 (en) | Human lcb kinase 1 | |
| AU784615B2 (en) | Human membrane proteins and polynucleotides encoding the same | |
| KR20240109203A (en) | System for editing mitochondrial base mutation of leber's hereditary optic neuropathy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210604 |
|
| RJ01 | Rejection of invention patent application after publication |